Prostate Cancer Drugs Market Commodities, High Growth Opportunities, Segmentation, Market Trends By 2024-2033|Astellas Pharma Inc., AstraZeneca PLC, Johnson & Johnson, Sanofi S.A., Bayer AG

The Prostate Cancer Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2011-2022) and extends its insights into a ten-year forecast period (2024-2033).

Learn More On The Prostate Cancer Drugs Market:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

According to The Business Research Company’s Prostate Cancer Drugs Global Market Report 2024, The prostate cancer drugs market size has grown strongly in recent years. It will grow from $17.36 billion in 2023 to $18.55 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to aging population, increased diagnoses, drug innovation, awareness and education, reimbursement and insurance.

The prostate cancer drugs market size is expected to see strong growth in the next few years. It will grow to $23.99 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to growing incidence, emerging markets, supportive government policies, r&d investments. Major trends in the forecast period include precision medicine, immunotherapy and targeted therapies, personalized medicine, clinical trials and drug pipeline, combination therapies, biomarker-driven treatments, telemedicine and remote monitoring.

The increasing men geriatric population is a major driver for the prostate cancer drugs market. Prostate cancer is one of the most common types of cancer in men aged above 60. According to ACL (Administration For Community Living), a US-based government organization, the geriatric population is expected to increase by 21.6% by 2040. Among those population, men are affected more with prostate cancer than women. For example, in January 2022, according to American Cancer Society, a US-based organization, prostate cancer develops in older men and in non-hispanicblack menand about 6 cases in 10 are diagnosed in men who are 65 or older (geriatric population). Therefore, increasing men geriatric population drives the growth of the prostate cancer market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample_request?id=2592&type=smp

The prostate cancer drugs market covered in this report is segmented –

1) By Type: Hormone Sensitive Prostate Cancer; Hormone Refractory Prostate Cancer

2) By Therapy: Hormonal Therapy; Chemotherapy; Immunotherapy; Targeted Therapy

3) By End User: Hospitals; Clinics; Other End-Users

The prostate cancer drugs market report table of contents includes: